

To NASDAQ OMX Copenhagen A/S

Translation

Company release No 5/2011

Hørsholm
1 April 2011

Report on the annual general meeting of ALK-Abelló A/S and the first meeting of the Board of Directors held on 1 April 2011

Page 1/2

The annual general meeting of ALK held on 1 April 2011 transacted the following business:

- Adoption of the annual report 2010 and discharge of the Board of Directors and Board of Management.
- Declaration of an ordinary dividend of DKK 5.00 per A/B share of DKK 10.
- The Board of Directors was authorised for the period up to the next annual general meeting to let the company acquire own B shares with a nominal value of up to 10% of the share capital at the market price for B shares on the date of acquisition, subject to a deviation of up to 10%.
- The Board of Directors was authorised for the period up to and including the day of the annual general meeting to be held in 2012 to increase the company's share capital by issue of new shares having a nominal value of up to DKK 10,128,360, equivalent to A shares having a nominal value of up to DKK 920,760 and B shares having a nominal value of up to DKK 9,207,600.
- The Board of Directors was authorised to issue warrants to executives and senior managers to subscribe up to DKK 2,800,000 nominal value of B share capital in the company, equivalent to 280,000 B shares of DKK 10, and to increase the share capital in connection therewith. The authorisation is in force up to 31 March 2016.
- Lars Holmqvist, Thorleif Krarup, Anders Gersel Pedersen and Brian Petersen were re-elected to the Board of Directors. Steen Riisgaard, CEO of Novozymes A/S, and Jes Østergaard were newly elected to the Board of Directors.
- DELOITTE Statsautoriseret Revisionsaktieselskab was re-appointed as the company's auditor.

New Chairman and Vice Chairman of the Board of Directors

Following the annual general meeting, the Board of Directors held its first meeting. Thorleif Krarup was elected Chairman and Lars Holmqvist was elected Vice Chairman.

Thorleif Krarup has agreed to fill the post of Chairman up to the annual general meeting in 2012. He says: "ALK has a good platform for further growth and progress. The new Board of Directors has strong competences, and I am looking forward to leading the work of realising ALK's global strategy in the coming year."

In 2012, Steen Riisgaard will stand for Chairman of the Board of Directors, assuming he is re-elected to the Board in 2012. Thorleif Krarup says: "Steen Riisgaard will be a perfect candidate for Chairman of the Board of Directors by virtue of his many years of experience within management and board work as well as experience in research and development and sales and marketing in international companies."

ALK's Chairman up to now, Jørgen Worning, did not re-stand due to having reached the age limit for board members at ALK and Nils Axelsen did not seek re-election.

The Board of Directors resolved to appoint two board committees: an audit committee comprising Lars Holmqvist (chairman), Thorleif Krarup and Brian Petersen; and a remuneration committee comprising Jes Østergaard (chairman), Anders Gersel Pedersen and Steen Riisgaard.

ALK-Abelló A/S

Thorleif Krarup
Chairman

For further information, please contact:

Jens Bager, President and CEO, tel. +45 4574 7576

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy vaccination (immunotherapy) and has approximately 1,700 employees, subsidiaries, production facilities and distributors world wide. ALK has entered into partnership agreements with Merck and Torii Pharmaceutical Co., Ltd. regarding tablet based immunotherapy in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on the NASDAQ OMX Copenhagen A/S. Find more information at www.alk-abello.com.